- Phare
- Validé par KD/KO
Anticorps Polyclonal de lapin anti-PD-L1/CD274 (C-terminal)
PD-L1/CD274 (C-terminal) Polyclonal Antibody for IHC
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain, rat, souris
Applications
IHC
Conjugaison
Biotin
N° de cat : Biotin-28076
Synonymes
Galerie de données de validation
Applications testées
Résultats positifs en IHC | tissu d'amygdalite humain, tissu placentaire humain il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. |
Dilution recommandée
Application | Dilution |
---|---|
Immunohistochimie (IHC) | IHC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Informations sur le produit
Biotin-28076 cible PD-L1/CD274 (C-terminal) dans les applications de IHC et montre une réactivité avec des échantillons Humain, rat, souris
Réactivité | Humain, rat, souris |
Hôte / Isotype | Lapin / IgG |
Clonalité | Polyclonal |
Type | Anticorps |
Immunogène | PD-L1/CD274 (C-terminal) Protéine recombinante Ag27557 |
Nom complet | CD274 molecule |
Masse moléculaire calculée | 290 aa, 33 kDa |
Poids moléculaire observé | 45-50 kDa |
Numéro d’acquisition GenBank | BC074984 |
Symbole du gène | CD274 |
Identification du gène (NCBI) | 29126 |
Conjugaison | Biotin |
Forme | Liquide |
Méthode de purification | Purification par affinité contre l'antigène |
Tampon de stockage | PBS avec glycérol à 50 %, Proclin300 à 0,05 % et BSA à 0,5 %, pH 7,3. |
Conditions de stockage | Stocker à -20 °C. Éviter toute exposition à la lumière. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis.
What is the molecular weight of PD-L1?
Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176-290 aa).
What are the isoforms of PD-L1?
According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions.
What is the subcellular localization and tissue specificity of PD-L1?
It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues.
What is the function of PD-L1 in immune responses?
PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681).
How can PD-L1's implication in cancer be used as a drug target?
In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375).
Protocole
Product Specific Protocols | |
---|---|
IHC protocol for Biotin PD-L1/CD274 (C-terminal) antibody Biotin-28076 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |